Results of Operations and Financial Condition

Odyssey Therapeutics, Inc. (ODTX) - Form 8-K Summary

Business Context and Reporting Period

Odyssey Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on June 17, 2026. The filing announces the financial results for the three months ended March 31, 2026. The Company is classified as an emerging growth company.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that results were announced and directs readers to the attached press release (Exhibit 99.1) for detailed financial data.

Material Changes

No material changes versus the prior comparable period are detailed in the text of this Form 8-K. Specific comparative financial data is not included in the provided content.

Guidance, Outlook, and Risks

The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The information is intended to be furnished and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated June 17, 2026) for actual revenue, net loss, and cash position figures.
  • Verify the Company's cash runway and burn rate based on the Q1 2026 results.
  • Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
  • Confirm if the Company has elected to use the extended transition period for new accounting standards as an emerging growth company.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.